Global Vitiligo Market, Patients By Countries (United States, United Kingdom, France, Germany, Italy, India, China, Japan), Drugs (ARN-4079, ATI-502, AX-1602, BOS-47, CCP-070, Cerdulatinib (RVT-502), HuABC-2, Abatacept, Topical Ruxolitinib, VLRX-001) Companies (AXIM Biotechnologies, Incyte Corporation, Bristol-Myers Squibb, Clinuvel Pharmaceuticals), Clinical Study, Growth Drivers, Challenges

December 2018 | | ID: G899C6199FEEN
Renub Research

Abstracts

Vitiligo is a long-term skin disease in which patches of the skin lose their color. The skin patches affected by the disease Vitiligo become white. This happens because melanocytes within the skin die off. The skin pigmentation, melanin, due to which skin has its color, protection from sun UV rays this all happens because of melanocytes cells. Growing per capita healthcare expenditure, improving healthcare infrastructure in developing countries, growing diseases awareness and expected approval of Vitiligo drugs are some of the driving force for the growth of this market. However, shortage of dermatologists and available treatments having longer duration of times are major challenges for the growth of this market. According to Renub Research global Vitiligo market will be US$ 2.4 Billion by the year 2024.

Vitiligo disease prevalence varies between race, regions and countries. It is expected that overall prevalence fall between 1-2 percent of the total population. Although Vitiligo disease can arise at any age, it mostly occurs to young and middle age people. At present globally over 21 Million people has suffered from this diseases. There are number of drugs manufactures working for Vitiligo drugs development across various parts of the globe such as AXIM Biotechnologies, Boston Pharmaceutical, Castle Creek Pharma, Dermavant Sciences, JN Biosciences, Bristol-Myers Squibb, Incyte Corporation, Clinuvel Pharmaceuticals etc. and their Vitiligo drugs development are in various stages.

Renub Research report titled “Global Vitiligo Market, Patients By Countries (United States, United Kingdom, France, Germany, Italy, India, China, Japan), Drugs (ARN-4079, ATI-502, AX-1602, BOS-47, CCP-070, Cerdulatinib (RVT-502), HuABC-2, Abatacept, Topical Ruxolitinib, VLRX-001) Companies (AXIM Biotechnologies, Incyte Corporation, Bristol-Myers Squibb, Clinuvel Pharmaceuticals), Clinical Study, Growth Drivers, Challenges” provides a complete analysis of global vitiligo drugs market.

India and China are Key Contributors in the Global Vitiligo Patient Population

Vitiligo patient’s population is growing across all parts of the world. Patient’s growth rates varies in the countries covered in the report United States, United Kingdom, France, Germany, Italy, India, China and Japan. India and China are key contributors in the global vitiligo patient population.

Vitiligo Pipe Line Drugs are Key Strength for this Market Place

In the global vitiligo market, vitiligo pipe line drugs will play the major role for the growth of this market. At present several drugs such as ARN-4079, ATI-502, AX-1602, BOS-47, CCP-070, Cerdulatinib (RVT-502), HuABC-2, Abatacept, Topical Ruxolitinib, VLRX-001 etc. are in preclinical, IND, Phase I, Phase II and Phase III stage.

Key Drugs Development Companies are working in this Market Place

Key drugs development companies are working in this market place across various parts of the globe such as AXIM Biotechnologies, Boston Pharmaceutical, Castle Creek Pharma, Dermavant Sciences, JN Biosciences, Bristol-Myers Squibb, Incyte Corporation, Clinuvel Pharmaceuticals etc.

Segments - Global Vitiligo Market

• Vitiligo Patients Population
• Vitiligo Market

Countries - Global Vitiligo Market

• United States
• United Kingdom
• France
• Germany
• Italy
• India
• China
• Japan

Global Vitiligo Market – Drugs Profile Covered

• ARN-4079
• ATI-502
• AX-1602
• BOS-47
• CCP-070
• Cerdulatinib (RVT-502)
• HuABC-2
• Abatacept
• Topical Ruxolitinib
• VLRX-001

Companies Covered

• AXIM Biotechnologies
• Incyte Corporation
• Bristol-Myers Squibb
• Clinuvel Pharmaceuticals

Each Company Covered in this Report has Following Details

• Company Overview
• Company Initiatives
• Financial Insight

Contents

1. INTRODUCTION

1.1 Market Definition

2. RESEARCH METHODOLOGY

3. EXECUTIVE SUMMARY

4. GLOBAL VITILIGO PATIENT NUMBERS & MARKET

4.1 Vitiligo Patients Numbers
4.2 Vitiligo Market

5. SHARE – GLOBAL VITILIGO PATIENT NUMBERS & MARKET

5.1 Vitiligo Patient Numbers Share
5.2 Vitiligo Market Share

6. UNITED STATES

6.1 Vitiligo Patient Numbers
6.2 Vitiligo Market

7. UNITED KINGDOM

7.1 Vitiligo Patient Numbers
7.2 Vitiligo Market

8. FRANCE

8.1 Vitiligo Patient Numbers
8.2 Vitiligo Market

9. GERMANY

9.1 Vitiligo Patient Numbers
9.2 Vitiligo Market

10. ITALY

10.1 Vitiligo Patient Numbers
10.2 Vitiligo Market

11. INDIA

11.1 Vitiligo Patient Numbers
11.2 Vitiligo Market

12. CHINA

12.1 Vitiligo Patient Numbers
12.2 Vitiligo Market

13. JAPAN

13.1 Vitiligo Patient Numbers
13.2 Vitiligo Market

14. VITILIGO PIPE LINE DRUGS

14.1 ARN-4079
14.2 ATI-502
14.3 AX-1602
14.4 BOS-475
14.5 CCP-070
14.6 Cerdulatinib (RVT-502)
14.7 HuABC-2
14.8 Abatacept
14.9 Topical Ruxolitinib
14.10 VLRX-001

15. CLINICAL STUDY OF VITILIGO MARKET

16. GROWTH DRIVERS

16.1 Growing Importance of Aesthetic Appeal
16.2 World Vitiligo Day: Increases Vitiligo Awareness

17. GLOBAL VITILIGO MARKET – CHALLENGES

17.1 Shortage of Dermatologists
17.2 Available Treatments are Not Much Effective

18. AXIM BIOTECHNOLOGIES, INC.

18.1 Company Overview
18.2 Initiatives
  18.2.1 Point
  18.2.2 Point
  18.2.3 Point
18.3 Financial Insight

19. INCYTE CORPORATION

19.1 Company Overview
19.2 Initiatives
  19.2.1 Point
  19.2.2 Point
19.3 Financial Insight

20. BRISTOL-MYERS SQUIBB

20.1 Company Overview
20.2 Initiatives
  20.2.1 Point
  20.2.2 Point
20.3 Financial Insight

21. CLINUVEL PHARMACEUTICALS LTD

21.1 Company Overview
21.2 Company Initiatives
  21.2.1 Point
  21.2.2 Point
21.3 Financial Insight

List Of Figures

LIST OF FIGURES:

Figure 4 1: Global – Vitiligo Patients Population (Thousand), 2012 – 2017
Figure 4 2: Global – Forecast for Vitiligo Patients Population (Thousand), 2018 – 2024
Figure 4 3: Global – Vitiligo Market (Million US$), 2012 – 2017
Figure 4 4: Global – Forecast for Vitiligo Market (Million US$), 2018 – 2024
Figure 5 1: Global – Vitiligo Patients Population Share (Percent), 2012 – 2017
Figure 5 2: Global – Forecast for Vitiligo Patients Population Share (Percent), 2018 – 2024
Figure 5 3: Global – Vitiligo Market Share (Percent), 2012 – 2017
Figure 5 4: Global – Forecast for Vitiligo Market Share (Percent), 2018 – 2024
Figure 6 1: United States – Vitiligo Patients Population (Thousand), 2012 – 2017
Figure 6 2: United States – Forecast for Vitiligo Patients Population (Thousand), 2018 – 2024
Figure 6 3: United States – Vitiligo Market (Million US$), 2012 – 2017
Figure 6 4: United States – Forecast for Vitiligo Market (Million US$), 2018 – 2024
Figure 7 1: United Kingdom – Vitiligo Patients Population (Thousand), 2012 – 2017
Figure 7 2: United Kingdom – Forecast for Vitiligo Patients Population (Thousand), 2018 – 2024
Figure 7 3: United Kingdom – Vitiligo Market (Million US$), 2012 – 2017
Figure 7 4: United Kingdom – Forecast for Vitiligo Market (Million US$), 2018 – 2024
Figure 8 1: France – Vitiligo Patients Population (Thousand), 2012 – 2017
Figure 8 2: France – Forecast for Vitiligo Patients Population (Thousand), 2018 – 2024
Figure 8 3: France – Vitiligo Market (Million US$), 2012 – 2017
Figure 8 4: France – Forecast for Vitiligo Market (Million US$), 2018 – 2024
Figure 9 1: Germany – Vitiligo Patients Population (Thousand), 2012 – 2017
Figure 9 2: Germany – Forecast for Vitiligo Patients Population (Thousand), 2018 – 2024
Figure 9 3: Germany – Vitiligo Market (Million US$), 2012 – 2017
Figure 9 4: Germany – Forecast for Vitiligo Market (Million US$), 2018 – 2024
Figure 10 1: Italy – Vitiligo Patients Population (Thousand), 2012 – 2017
Figure 10 2: Italy – Forecast for Vitiligo Patients Population (Thousand), 2018 – 2024
Figure 10 3: Italy – Vitiligo Market (Million US$), 2012 – 2017
Figure 10 4: Italy – Forecast for Vitiligo Market (Million US$), 2018 – 2024
Figure 11 1: India – Vitiligo Patients Population (Thousand), 2012 – 2017
Figure 11 2: India – Forecast for Vitiligo Patients Population (Thousand), 2018 – 2024
Figure 11 3: India – Vitiligo Market (Million US$), 2012 – 2017
Figure 11 4: India – Forecast for Vitiligo Market (Million US$), 2018 – 2024
Figure 12 1: China – Vitiligo Patients Population (Thousand), 2012 – 2017
Figure 12 2: China – Forecast for Vitiligo Patients Population (Thousand), 2018 – 2024
Figure 12 3: China – Vitiligo Market (Million US$), 2012 – 2017
Figure 12 4: China – Forecast for Vitiligo Market (Million US$), 2018 – 2024
Figure 13 1: Japan – Vitiligo Patients Population (Thousand), 2012 – 2017
Figure 13 2: Japan – Forecast for Vitiligo Patients Population (Thousand), 2018 – 2024
Figure 13 3: Japan – Vitiligo Market (Million US$), 2012 – 2017
Figure 13 4: Japan – Forecast for Vitiligo Market (Million US$), 2018 – 2024
Figure 14 1: Vitiligo Pipe Line Drug – ARN-4079 Status (2018)
Figure 14 2: Vitiligo Pipe Line Drug – ATI-502 Status (2018)
Figure 14 3: Vitiligo Pipe Line Drug – AX-1602 Status (2018)
Figure 14 4: Vitiligo Pipe Line Drug – BOS-475 Status (2018)
Figure 14 5: Vitiligo Pipe Line Drug – CCP-070 Status (2018)
Figure 14 6: Vitiligo Pipe Line Drug – Cerdulatinib (RVT-502) Status (2018)
Figure 14 7: Vitiligo Pipe Line Drug – HuABC-2 Status (2018)
Figure 14 8: Vitiligo Pipe Line Drug – Abatacept Status (2018)
Figure 14 9: Vitiligo Pipe Line Drug – Topical Ruxolitinib Status (2018)
Figure 14 10: Vitiligo Pipe Line Drug – VLRX-001 Status (2018)
Figure 18 1: Axim Biotechnologies, Inc – Global Sales (US$), 2015 - 2017
Figure 18 2: Axim Biotechnologies, Inc – Forecast for Global Sales (US$), 2018 - 2024
Figure 19 1: Incyte Corporation – Global Sales (Million US$), 2012 - 2017
Figure 19 2: Incyte Corporation – Forecast for Global Sales (Million US$), 2018 - 2024
Figure 20 1: Bristol-Myers Squibb – Global Sales (Million US$), 2012 - 2017
Figure 20 2: Bristol-Myers Squibb – Forecast for Global Sales (Million US$), 2018 - 2024
Figure 21 1: Clinuvel Pharmaceuticals Limited – Global Sales (Thousand US$), 2013 - 2017
Figure 21 2: Clinuvel Pharmaceuticals Limited – Forecast for Global Sales (Thousand US$), 2018 - 2024

List Of Tables

LIST OF TABLES:

Table 15-1: Global – Vitiligo Market Clinical Study, 2018